Poster presentation from 2001. Itās the only thing I can find so far that directly addresses this issue in humans, but it would be nice to have something better.
Knopp, R. H., Bays, H., Manion, C. V., Lipka, L. J., Melani, L., LeBeaut, A. P., ā¦ Veltri, E. P. (2001). Atherosclerosis Supplements, 2(2), 90.* doi:10.1016/s1567-5688(01)80226-9
EFFECT OF EZETIMIBE ON SERUM CONCENTRATIONS
OF LIPID-SOLUBLE VITAMINS
R.H. Knoppā , H. Bays*, C.V Manion3, L.J. Lipka4, L. Melani4,
AI? LeBeaut4, R Suresh4, E.P. Veltri4. The Ezetimibe Study Group;
āNorthwest Lipid Research Clinic, Seattle, WA; 2L-MARC Research Center,
Louisville, KX 30klahoma Medical Research Foundation, Oklahoma City,
OK; 4Schering-Plough Research Institute, Kenilwotih, NJ, USA
Purpose: To determine the effect of the novel selective cholesterol absorption inhibitor ezetimibe (EZE) on serum concentrations of lipid-soluble
vitamins.
Methods: In a randomized, double-blind, placebo-controlled study to
evaluate the safety and efficacy of EZE, serum concentrations of vitamins
A, D (25-hydroxy vitamin D and 1,25-dihydroxy vitamin D), the two major
components of vitamin E (a- and y-tocopherol), and the a- and S-carotenoids
were measured at baseline and after 12 weeks of once-daily therapy with
either EZE 10 mg (n = 85) or placebo (PBO; n = 28) at a subset of the
study centers. Prothrombin time (PT), an indicator of vitamin K, was also
assessed.
Results: For all subjects, levels of vitamin A, a-tocopherol, and 1,25-
dihydroxy vitamin D were 3 normal levels at baseline and remained 2
normal after 12 weeks of therapy. All PBO subjects had normal a- and
p-carotene levels at baseline and at 12 weeks. a- and p-carotene levels
were normal at baseline and at 12 weeks for 82 (97%) and 78 (92%) EZE
subjects, respectively; 2 and 4 EZE subjects, respectively, had < normal
levels at baseline with 2 and 1, respectively, normalizing at 12 weeks; 1
and 3, respectively, had normal levels at baseline and < normal at 12 weeks.
Twenty-three (82%) PBO subjects had normal y-tocopherol levels at baseline
and at 12 weeks, 3 had < normal at baseline normalizing at 12 weeks, and 2
had normal levels at baseline and < normal at 12 weeks. Seventy-two (85%)
EZE subjects had normal y-tocopherol levels at baseline and at 12 weeks,
10 had < normal levels at baseline with 5 normalizing at 12 weeks, and 3
had normal levels at baseline and < normal at 12 weeks. One PBO and 1
EZE subject had 25-hydroxy vitamin D levels c normal at baseline. Both
had normal levels at 12 weeks. PT was unatfected by EZE treatment.
Conclusions: EZE does not alter lipid-soluble vitamin status.
